Literature DB >> 11025595

An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients.

A N Blanco1, A A Peirano, S H Grosso, L C Gennari, R P Bianco, M A Lazzari.   

Abstract

BACKGROUND AND OBJECTIVES: Difficulties in identifying the coexistence of neutralizing anti-factor VIII antibodies (anti-fVIII) and lupus anticoagulant (LA) are mainly due to the interference of LA on anti-fVIII assays. Our aim was to reveal the presence of anti-fVIII using a system that is not affected by LA. DESIGN AND METHODS: We developed an enzyme-linked immunosorbent assay (ELISA) method that uses phospholipid-free recombinant factor VIII as the antigen. A monoclonal anti-fVIII was tested as a positive control, excluding non-specific binding by using two unrelated monoclonal antibodies. The ELISA was performed on hemophilic plasmas with anti-fVIII and negative LA (n=12) or without inhibitors (n=12). Two hemophilic plasmas with LA and presumably anti-fVIII were also assayed. Positive LA (n=12) and normal (n=10) plasmas were tested as negative controls.
RESULTS: All (12/12) plasmas with anti-fVIII and 5/12 hemophilic plasmas without inhibitors were positive; LA and normal plasma controls were negative. INTERPRETATION AND
CONCLUSIONS: Results presented here show that LA does not interfere with the anti-fVIII ELISA: However, the assay detects both neutralizing and non-neutralizing anti-fVIII antibodies, therefore a neutralizing effect must be confirmed through functional tests.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025595

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.

Authors:  Albain Chansavang; Aurélien Philippe; Ines Bozinovic; Khalil Ben Hadj Ali; David Smadja; Dominique Helley; Luc Darnige; Laetitia Mauge
Journal:  Ann Hematol       Date:  2022-09-20       Impact factor: 4.030

2.  Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Authors:  C H Miller; A S Rice; B Boylan; A D Shapiro; S R Lentz; B M Wicklund; F M Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

3.  Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.

Authors:  Yoshihiko Sakurai; Tomohiro Takeda
Journal:  J Immunol Res       Date:  2014-03-24       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.